Thromboprophylaxis in a patient with COVID‐19 and severe hemophilia A on emicizumab prophylaxis

COVID‐19 can be associated with coagulopathy (CAC, COVID‐19‐associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thromb Haemost
Autores principales: Rivas‐Pollmar, María Isabel, Álvarez‐Román, María Teresa, Butta‐Coll, Nora V., Martín Salces, Mónica, García‐Barcenilla, Sara, Jiménez‐Yuste, Victor
Formato: Artigo
Lenguaje:Inglês
Publicado: International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2020
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307111/
https://ncbi.nlm.nih.gov/pubmed/32526092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14954
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares